Aliases & Classifications for Uterine Anomalies

MalaCards integrated aliases for Uterine Anomalies:

Name: Uterine Anomalies 58
Uterine Diseases 56 44 45 74
Uterine Disease 12 15
Uterine Abnormality 56

Characteristics:

OMIM:

58
Inheritance:
autosomal dominant


HPO:

33
uterine anomalies:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:345
OMIM 58 192000
ICD9CM 36 621.9
MeSH 45 D014591
NCIt 51 C26907
SNOMED-CT 69 12337004
ICD10 34 N85.9
MedGen 43 C0266383
SNOMED-CT via HPO 70 263681008 31401003
UMLS 74 C0042131

Summaries for Uterine Anomalies

MedlinePlus : 44 The uterus, or womb, is the place where a baby grows when a woman is pregnant. The first sign of a problem with the uterus may be bleeding between periods or after sex. Causes can include hormones, thyroid problems, fibroids, polyps, cancer, infection, or pregnancy. Treatment depends on the cause. Sometimes birth control pills treat hormonal imbalances. If a thyroid problem is the cause, treating it may also stop the bleeding. If you have cancer or hyperplasia, an overgrowth of normal cells in the uterus, you may need surgery. With two other uterine problems, tissue that normally lines the uterus grows where it is not supposed to. In endometriosis, it grows outside the uterus. In adenomyosis, it grows in the uterus's outside walls. Pain medicine may help. Other treatments include hormones and surgery.

MalaCards based summary : Uterine Anomalies, also known as uterine diseases, is related to adenomyosis and endometrial disease, and has symptoms including pelvic pain An important gene associated with Uterine Anomalies is ESR1 (Estrogen Receptor 1), and among its related pathways/superpathways are Endometrial cancer and Glioma. The drugs Hyaluronic acid and Iodine have been mentioned in the context of this disorder. Affiliated tissues include the uterus, cervix and testes, and related phenotypes are bicornuate uterus and Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435)

Disease Ontology : 12 A female reproductive system disease that is located in the uterus.

Description from OMIM: 192000

Related Diseases for Uterine Anomalies

Diseases in the Uterine Anomalies family:

Uterine Inflammatory Disease

Diseases related to Uterine Anomalies via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 183)
# Related Disease Score Top Affiliating Genes
1 adenomyosis 32.6 CYP19A1 ESR1 PGR
2 endometrial disease 32.1 CYP19A1 ESR1 OXT
3 placenta disease 32.0 CSH1 CSH2 OXT
4 cervix disease 31.7 CDKN2A GP5 INSM1 MAPK8IP1 MAPK8IP2 PTPRN
5 endometriosis 30.4 CYP19A1 ESR1 PGR PTEN
6 hemometra 30.4 MAPK8IP1 OXT PTPRN
7 endometritis 30.2 ESR1 OXT PGR
8 endometrial cancer 29.9 CDKN2A CYP19A1 ESR1 MLH1 MSH2 MSH6
9 acrorenal-mandibular syndrome 11.0
10 pyometritis 10.9
11 female infertility of uterine origin 10.9
12 uterine inflammatory disease 10.9
13 chronic subinvolution of uterus 10.9
14 adhesions of uterus 10.9
15 uterine inversion 10.9
16 vestibular gland benign neoplasm 10.6 ESR1 PGR
17 bartholin's gland adenoma 10.6 ESR1 PGR
18 endometrium carcinoma in situ 10.6 PGR TP53
19 breast duct papilloma 10.6 PGR PTEN
20 vulvar syringoma 10.6 ESR1 PGR
21 lung leiomyoma 10.6 ESR1 PGR
22 carcinosarcoma 10.6 PGR PTEN TP53
23 glassy cell carcinoma of the cervix 10.6 ESR1 PGR
24 progesterone-receptor positive breast cancer 10.6 CYP19A1 ESR1 PGR
25 gender identity disorder 10.6 CYP19A1 ESR1 PGR
26 early invasive cervical adenocarcinoma 10.6 CDKN2A INSM1
27 estrogen excess 10.6 CYP19A1 ESR1 PGR
28 mammographic density 10.6 CYP19A1 ESR1 PGR
29 small cell carcinoma 10.6 CDKN2A PTEN TP53
30 microinvasive cervical squamous cell carcinoma 10.6 INSM1 PTPRN
31 bartholin's gland benign neoplasm 10.6 CDKN2A ESR1 PGR
32 endocervical carcinoma 10.6 CDKN2A ESR1 MAPK8IP1
33 endometrial squamous cell carcinoma 10.6 CDKN2A ESR1 PGR
34 endometrial mucinous adenocarcinoma 10.6 CDKN2A ESR1 PGR
35 adenoid basal cell carcinoma 10.6 CDKN2A ESR1 PGR
36 adenosarcoma 10.6 ESR1 PGR TP53
37 vulvar benign neoplasm 10.6 ESR1 PGR
38 breast benign neoplasm 10.6 ESR1 PGR TP53
39 trigonitis 10.6 ESR1 PGR
40 thoracic benign neoplasm 10.6 ESR1 PGR TP53
41 testicular trophoblastic tumor 10.6 CSH1 CSH2
42 prostatic hypertrophy 10.6 CYP19A1 ESR1 PGR
43 uterine corpus cancer 10.6 ESR1 PGR TP53
44 vulvar leiomyoma 10.6 ESR1 PGR
45 reproductive organ benign neoplasm 10.6 CYP19A1 ESR1 PGR
46 bartholin's gland disease 10.6 CDKN2A PGR TP53
47 juvenile nasopharyngeal angiofibroma 10.6 CYP19A1 ESR1 PGR
48 fallopian tube carcinoma 10.6 ESR1 PGR TP53
49 anal squamous cell carcinoma 10.6 CDKN2A MLH1 TP53
50 endometrial stromal nodule 10.5 CYP19A1 NDUFB11 PGR

Graphical network of the top 20 diseases related to Uterine Anomalies:



Diseases related to Uterine Anomalies

Symptoms & Phenotypes for Uterine Anomalies

Human phenotypes related to Uterine Anomalies:

33
# Description HPO Frequency HPO Source Accession
1 bicornuate uterus 33 HP:0000813

Symptoms via clinical synopsis from OMIM:

58
G U:
uterine anomalies
uterus arcuatus
uterus bicornis unicollis

Clinical features from OMIM:

192000

UMLS symptoms related to Uterine Anomalies:


pelvic pain

GenomeRNAi Phenotypes related to Uterine Anomalies according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) GR00104-A-0 8.92 ESR1 MSH2 PTEN PTPRN

MGI Mouse Phenotypes related to Uterine Anomalies:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.31 CDKN2A CYP19A1 ESR1 GP5 HNF1B INSM1
2 endocrine/exocrine gland MP:0005379 10.25 CDKN2A CYP19A1 ESR1 HNF1B INSM1 MAPK8IP1
3 cellular MP:0005384 10.22 CDKN2A CYP19A1 ESR1 INSM1 MAPK8IP1 MLH1
4 digestive/alimentary MP:0005381 10.11 CDKN2A CYP19A1 ESR1 INSM1 MLH1 MSH2
5 immune system MP:0005387 10.11 CDKN2A CYP19A1 ESR1 HNF1B MLH1 MSH2
6 integument MP:0010771 10.02 CDKN2A CYP19A1 ESR1 MLH1 MSH2 MSH6
7 mortality/aging MP:0010768 9.97 CDKN2A ESR1 HNF1B INSM1 MAPK8IP1 MAPK8IP2
8 liver/biliary system MP:0005370 9.8 CDKN2A CYP19A1 ESR1 HNF1B MAPK8IP1 PTEN
9 neoplasm MP:0002006 9.56 CDKN2A ESR1 MLH1 MSH2 MSH6 PGR
10 reproductive system MP:0005389 9.32 CDKN2A CYP19A1 ESR1 MAPK8IP1 MAPK8IP2 MLH1

Drugs & Therapeutics for Uterine Anomalies

Drugs for Uterine Anomalies (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 721)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hyaluronic acid Approved, Vet_approved Phase 4,Not Applicable 9004-61-9 53477741
2
Iodine Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable,Early Phase 1 7553-56-2 807
3
Povidone Approved Phase 4,Not Applicable 9003-39-8
4
Povidone-iodine Approved Phase 4,Not Applicable 25655-41-8
5
Levonorgestrel Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 797-63-7, 17489-40-6 13109
6
Norethindrone Approved Phase 4,Phase 3,Phase 2,Not Applicable 68-22-4 6230
7
Azithromycin Approved Phase 4,Phase 3,Not Applicable 83905-01-5 447043 55185
8
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 564-25-0 54671203
9
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
10
Lymecycline Approved, Investigational Phase 4 992-21-2 5280963
11
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 28014-46-2
12
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 50-28-2 5757
13
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 143 6006
14
Progesterone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1 57-83-0 5994
15
Bupivacaine Approved, Investigational Phase 4,Not Applicable 38396-39-3, 2180-92-9 2474
16
Medroxyprogesterone acetate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 71-58-9
17
Tranexamic Acid Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 1197-18-8 5526
18
Tamoxifen Approved Phase 4,Phase 3,Phase 2 10540-29-1 2733526
19
Copper Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 7440-50-8 27099
20
Misoprostol Approved Phase 4,Phase 3,Phase 2,Not Applicable 59122-46-2 5282381
21
Acetaminophen Approved Phase 4,Phase 2 103-90-2 1983
22
Ethanol Approved Phase 4,Not Applicable 64-17-5 702
23
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
24
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Not Applicable 437-38-7 3345
25
Clindamycin Approved, Vet_approved Phase 4,Not Applicable 18323-44-9 29029
26
Iron Approved, Experimental Phase 4,Phase 3,Phase 2,Phase 1 7439-89-6, 15438-31-0 27284 23925
27
Buserelin Approved, Investigational Phase 4,Phase 3 57982-77-1
28
Ethinyl Estradiol Approved Phase 4,Phase 2,Phase 1,Early Phase 1,Not Applicable 57-63-6 5991
29
Dalteparin Approved Phase 4,Phase 3 9005-49-6
30
Heparin Approved, Investigational Phase 4,Phase 3 9005-49-6 46507594 772
31
Enoxaparin Approved Phase 4 9005-49-6 772
32
Mepivacaine Approved, Vet_approved Phase 4 96-88-8 4062
33
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 657-24-9 14219 4091
34
Mefenamic acid Approved Phase 4,Phase 3,Not Applicable 61-68-7 4044
35
Ropivacaine Approved Phase 4,Not Applicable 84057-95-4 175805 71273
36
Chloroprocaine Approved Phase 4 133-16-4 8612
37
Procaine Approved, Investigational, Vet_approved Phase 4 59-46-1 4914
38
Naproxen Approved, Vet_approved Phase 4 22204-53-1 156391 1302
39
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
40
Dexmedetomidine Approved, Vet_approved Phase 4,Not Applicable 113775-47-6 5311068 68602
41
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
42
Ibuprofen Approved Phase 4 15687-27-1 3672
43
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 137-58-6 3676
44
Morphine Approved, Investigational Phase 4,Early Phase 1 57-27-2 5288826
45
Aprepitant Approved, Investigational Phase 4 170729-80-3 6918365 151165
46
Fosaprepitant Approved Phase 4 172673-20-0 219090
47
Bupropion Approved Phase 4,Phase 2 34841-39-9, 34911-55-2 444
48
Dopamine Approved Phase 4,Phase 2,Phase 1,Not Applicable 62-31-7, 51-61-6 681
49
Nicotine Approved Phase 4,Not Applicable 54-11-5 89594 942
50
Cefazolin Approved Phase 4,Not Applicable 25953-19-9 33255 656510

Interventional clinical trials:

(show top 50) (show all 2208)
# Name Status NCT ID Phase Drugs
1 Effectiveness of Hyaluronic Acid Gel in the Prevention of Intrauterine Adhesions After Second Trimester Abortion Unknown status NCT02868437 Phase 4
2 CavatermTM vs TCRE in Women With DUB Unknown status NCT00549159 Phase 4
3 Preoperative Vaginal Cleansing With Povidone Iodine and the Risk of Post Cesarean Endometritis Unknown status NCT02693483 Phase 4 10% povidone iodine
4 A New Treatment Option for Heavy Menstrual Bleeding Unknown status NCT01715025 Phase 4 E2Nomac
5 Pretreatment With Norethindrone Acetate Prior to Levonorgestrel IUS Insertion for Heavy Menstrual Bleeding Unknown status NCT01391052 Phase 4 Norethindrone acetate pretreatment
6 Surgical Treatment To Greater Anterior Vaginal Prolapse Unknown status NCT00676325 Phase 4
7 Comparative Study of Mesh Versus No Mesh in Prolapse Surgery Unknown status NCT00153257 Phase 4
8 The Efficacy of Tachosil® for Prevention of Hemorrhage After Loop Electrosurgical Excisional Procedure (LEEP) Unknown status NCT02629510 Phase 4 Tachosil
9 Time to Eradication of Mycoplasma Genitalium and Chlamydia Trachomatis After Treatment Commenced Unknown status NCT01661985 Phase 4 Azithromycin;Doxycycline;lymecycline
10 Can Alternative Treatment Have an Impact on Cervical Dysplasia? Unknown status NCT00842738 Phase 4
11 Prevention of Menstrual Migraines: Effects of Estrogen Add-back During the HFI in Patients Using Continuous Oral Contraceptives. Unknown status NCT01251263 Phase 4 Estradiol or Placebo;Estradiol or Placebo
12 Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls? Unknown status NCT01101750 Phase 4
13 Primary and Secondary Prevention of Human Papillomavirus (HPV) Disease in China Unknown status NCT01021904 Phase 4
14 Upper Vaginectomy Versus Brachytherapy in Patients With Early Stage Endometrial Cancer Treated With Laparoscopic Surgery Unknown status NCT00719017 Phase 4
15 Low Molecular Weight Heparin in Recurrent Miscarriage With Negative Antiphospholipid Antibodies Completed NCT01608347 Phase 4 LMWH+Folic acid;Folic Acid
16 Efficacy of 17 Alpha-hydroxyprogesterones Caproate for the Prevention of Preterm Delivery Completed NCT00331695 Phase 4 17 alpha-hydroxyprogesterones caproate
17 Implantation Failure and PGD Completed NCT00547781 Phase 4
18 Role of Intrauterine Cornual Block in Combination With Direct Cervical Block in Outpatient Endometrial Ablation Completed NCT01808898 Phase 4
19 Apoptotic Signaling Pathways in Rats With Endometrial Hyperplasia Completed NCT02872818 Phase 4 17β estradiol hemihydrate;Metformin;medroxyprogesterone acetate
20 Management of Initial Bleeding/Spotting Associated With the Levonorgestrel-releasing Intrauterine System (MIRENA) Completed NCT01295294 Phase 4 Tranexamic acid;Mefenamic acid;Placebo;Mirena (Levonorgestrel IUS, BAY86-5028)
21 Endometrial Ablation With Non-hysteroscopic Methods Completed NCT01173965 Phase 4
22 DMPA & High Dose Oral Progestin (MPA) Tablets in Outpatient Treatment of Acute Excessive Vaginal Bleeding Completed NCT01148420 Phase 4 Medroxyprogesterone 17-Acetate;medroxyprogesterone acetate
23 A Study Comparing Mirena and Systemic Progestin for Endometrial Hyperplasia Completed NCT01074892 Phase 4 Provera (medroxyprogesterone/progestin);Provera (medroxyprogesterone)
24 Comparison Between Transvaginal Mesh and Traditional Surgery for Pelvic Organ Prolapse Completed NCT00566917 Phase 4
25 Posterior IVS Versus Sacrospinous Suspension in Vaginal Vault Prolapse Repair Completed NCT00153231 Phase 4
26 Local Infiltration Analgesia With Ropivacaine in Posterior Vaginal Wall Prolapse:a Randomized, Double-Blind Study Completed NCT00769054 Phase 4 Ropivacaine;Isotonic NaCl
27 Clinical Assessment of the Total Vaginal Mesh Technique for Treatment of Genital Prolapse Completed NCT00196495 Phase 4
28 Does Preoperative Vaginal Preparation With Povidone-iodine Before Cesarean Delivery Reduce the Risk of Endometritis? Completed NCT01437228 Phase 4 povidone- iodine solution.;placebo
29 Doxycycline Prophylaxis at Vacuum Aspiration Trial Completed NCT00547170 Phase 4 Doxycycline pre-operatively;Doxycycline post-operatively
30 Tamoxifen to Reduce Unscheduled Bleeding in New Users of the Levonorgestrel-releasing Intrauterine System (LNG-IUS) Completed NCT02824224 Phase 4 Tamoxifen;Placebo (for Tamoxifen)
31 Tranexamic Acid in Adolescents With Heavy Menstrual Bleeding Completed NCT01846507 Phase 4 Tranexamic Acid
32 Vaginal Estrogens Comparative Trial on Pelvic Organ Prolapse Patients Completed NCT03032848 Phase 4 Conjugated Estrogen;Promestriene;Estriol;Vaginal Moisturizer - Cream
33 Efficacy Study of Vaginal Mesh for Anterior Prolapse Completed NCT00557882 Phase 4
34 Intrathecal Chloroprocaine vs. Bupivacaine for Cervical Cerclage Completed NCT03305575 Phase 4 Chloroprocaine;Bupivacaine
35 Copper IUD Treatment Observation Study Completed NCT02519231 Phase 4 Naproxen;Placebo
36 Chances for Success of CavatermTM Surgery as a Function of Uterus Probe Length Completed NCT01436903 Phase 4
37 Lysteda Pediatric Research Equity Act (PREA) Pharmacokinetic Study in Adolescent Females With Heavy Menstrual Bleeding Completed NCT01190150 Phase 4 tranexamic acid
38 Medical Therapy Versus Radiofrequency Endometrial Ablation in the Initial Treatment of Menorrhagia Completed NCT01165307 Phase 4 Estradiol 30mcg / Levonorgestrel 150mcg monophasic oral contraceptive pills;Naproxen sodium pills
39 Bleeding Pattern and User Satisfaction During Second Consecutive MIRENA® in Contraception and Treatment of Menorrhagia Completed NCT00393198 Phase 4 Levonorgestrel (Mirena, BAY86-5028);Cytotec;Placebo
40 Evaluation of Modified Treatment Regimens for Treatment of Heavy Menstrual Bleeding Using the HerOption® System Completed NCT00094536 Phase 4
41 The Assessment of Tranexamic Acid in Women With Menorrhagia Who Have Bleeding Disorders Completed NCT00904709 Phase 4 tranexamic acid
42 Application of Tachosil During Lymphadenectomy Completed NCT03752606 Phase 4
43 The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Completed NCT03384511 Phase 4 Apatinib
44 Effects of Wound Infiltration With Ketamine Versus Dexmedetomidine Added to Bupivacaine on Cytokines Completed NCT03164590 Phase 4 Ketamine;dexmedetomidine;bupivacaine
45 Comparing Health Services Interventions for the Prevention of HPV-related Cancer Completed NCT02837926 Phase 4
46 Effect of HPV Vaccination on Women Aged 25 Years Completed NCT02296255 Phase 4
47 Effectiveness of IV Acetaminophen and IV Ibuprofen in Reducing Post Procedural Pain in the UFE Procedure Completed NCT02227316 Phase 4 IV Ibuprofen;IV Acetaminophen;Intravenous placebo/Intravenous placebo
48 The Effect of Nutritional Counseling for Cancer Patients Completed NCT01962272 Phase 4
49 Efficacy Study of Vaginal Mesh for Prolapse Completed NCT00475540 Phase 4
50 V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110) Completed NCT01544478 Phase 4

Search NIH Clinical Center for Uterine Anomalies

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: uterine diseases

Genetic Tests for Uterine Anomalies

Anatomical Context for Uterine Anomalies

The Foundational Model of Anatomy Ontology organs/tissues related to Uterine Anomalies:

20
The Uterus

MalaCards organs/tissues related to Uterine Anomalies:

42
Cervix, Testes, Lymph Node, Uterus, T Cells, Ovary, Thyroid

Publications for Uterine Anomalies

Articles related to Uterine Anomalies:

(show top 50) (show all 139)
# Title Authors Year
1
Frequency and types of uterine anomalies during caesarean section. ( 30372654 )
2019
2
Three-dimensional ultrasound in the diagnosis and the classification of congenital uterine anomalies using the ESHRE/ESGE classification: a diagnostic accuracy study. ( 30661094 )
2019
3
Surgical management of congenital uterine anomalies (including indications and surgical techniques). ( 30910446 )
2019
4
The association between obstetrical history and preterm birth in women with uterine anomalies. ( 28651449 )
2018
5
Classification of Uterine Anomalies by 3-Dimensional Ultrasonography Using ESHRE/ESGE Criteria: Interobserver Variability. ( 28847221 )
2018
6
Outcome of assisted reproduction in women with congenital uterine anomalies: a prospective observational study. ( 29055072 )
2018
7
Re: Outcome of assisted reproduction in women with congenital uterine anomalies: a prospective observational study. M. Prior, A. Richardson, S. Asif, L. Polanski, M. Parris-Larkin, J. Chandler, L. Fogg, P. Jassal, J. G. Thornton, N. J. Raine-Fenning. Ultrasound Obstet Gynecol 2018; 51: 110-117. ( 29297614 )
2018
8
Uterine anomalies - Latin anatomy reigns. ( 30004644 )
2018
9
Laparoscopic-assisted vaginal hysterectomy versus vaginal hysterectomy for benign uterine diseases: a prospective, randomized, multicenter, double-blind trial (LAVA). ( 29302807 )
2018
10
Adverse effect analysis of high-intensity focused ultrasound in the treatment of benign uterine diseases. ( 29792359 )
2018
11
Undescended or absent ovary without uterine anomalies: systematic review and a single center's experience. ( 28116887 )
2017
12
Diagnosis and Management of Congenital Uterine Anomalies in Pregnancy. ( 28304417 )
2017
13
The association of plasma glucose, BHBA, and NEFA with postpartum uterine diseases, fertility, and milk production of Holstein dairy cows. ( 27793454 )
2017
14
Dynamics of the microbiota found in the vaginas of dairy cows during the transition period: Associations with uterine diseases and reproductive outcome. ( 28189315 )
2017
15
Molecular aspects of uterine diseases in dogs. ( 28815849 )
2017
16
Fundus Thickness Assessment by 3D Transvaginal Ultrasound Allows Metrics-Based Diagnosis and Treatment of Congenital Uterine Anomalies. ( 26085458 )
2017
17
Endometrial cancer with congenital uterine anomalies: 3 case reports and a literature review. ( 28118070 )
2017
18
Training Performance in Diagnosis of Congenital Uterine Anomalies With 3-Dimensional Sonography: A Learning Curve Cumulative Summation Analysis. ( 27872415 )
2016
19
Undescended or absent ovary without uterine anomalies: systematic review and a single-center experience. ( 27727203 )
2016
20
Congenital Uterine Anomalies and Uterine Rupture. ( 26990544 )
2016
21
A Modified Nerve-Sparing Panhysterectomy for Benign Uterine Diseases: Techniques and Evaluation of Postoperative Pelvic Dysfunctions. ( 25823505 )
2015
22
Contrast-enhanced ultrasound for evaluation of high-intensity focused ultrasound treatment of benign uterine diseases: retrospective analysis of contrast safety. ( 25906100 )
2015
23
Postpartum uterine diseases and their impacts on conception and days open in dairy herds in Italy. ( 26210315 )
2015
24
Characterization of peripartum rumination and activity of cows diagnosed with metabolic and uterine diseases. ( 26233440 )
2015
25
Association between HSD17B1 rs605059 polymorphisms and the risk of uterine diseases: a systemic review and meta-analysis. ( 26261478 )
2015
26
Pattern of Congenital Uterine Anomalies Among Infertile Women in Southwest Nigeria. ( 27678894 )
2015
27
Pictorial Review of Complications of Uterine Anomalies. ( 26601928 )
2015
28
Reliability of the European Society of Human Reproduction and Embryology/European Society for Gynaecological Endoscopy and American Society for Reproductive Medicine classification systems for congenital uterine anomalies detected using three-dimensional ultrasonography. ( 26158905 )
2015
29
Longitudinal vaginal septa with associated uterine anomalies: a case series. ( 25349941 )
2015
30
Does surgery improve live birth rates in patients with recurrent miscarriage caused by uterine anomalies? ( 25058627 )
2015
31
Effect of trace mineral supplementation on selected minerals, energy metabolites, oxidative stress, and immune parameters and its association with uterine diseases in dairy cattle. ( 24835975 )
2014
32
Diagnostic and prognostic markers for uterine diseases in dogs. ( 24947856 )
2014
33
Risk factors for uterine diseases on small- and medium-sized dairy farms determined by clinical, bacteriological, and cytological examinations. ( 25066047 )
2014
34
Clinical implications of congenital uterine anomalies: a meta-analysis of comparative studies. ( 25444500 )
2014
35
Usefulness of three dimensional transvaginal ultrasonography and hysterosalpingography in diagnosing uterine anomalies. ( 25011216 )
2014
36
A classification of congenital uterine anomalies predicting pregnancy outcomes. ( 24773088 )
2014
37
Polycystic ovarian syndrome and congenital uterine anomalies: the hidden common player. ( 24615567 )
2014
38
Innate immune gene variation and differential susceptibility to uterine diseases in Holstein cows. ( 23768650 )
2013
39
Accuracy of 3-dimensional sonography for diagnosis and classification of congenital uterine anomalies. ( 23716512 )
2013
40
Effect of prior birth and miscarriage frequency on the prevalence of acquired and congenital uterine anomalies in women with recurrent miscarriage: a cross-sectional study. ( 23472945 )
2013
41
Use of 3-dimensional sonography to assess uterine anomalies. ( 23269704 )
2013
42
Enzymes of the AKR1B and AKR1C Subfamilies and Uterine Diseases. ( 22419909 )
2012
43
Association between virulence factors of Escherichia coli, Fusobacterium necrophorum, and Arcanobacterium pyogenes and uterine diseases of dairy cows. ( 22186615 )
2012
44
Imaging diagnosis of uterine anomalies. ( 22808635 )
2012
45
Pregnant uterine anomalies may be difficult to diagnose only by 2-dimensional ultrasound. ( 22727218 )
2012
46
Effects of postpartum uterine diseases on milk production and culling in dairy cows. ( 21338799 )
2011
47
Congenital uterine anomalies and adverse pregnancy outcomes. ( 21907963 )
2011
48
Reproductive outcomes in women with congenital uterine anomalies: a systematic review. ( 21830244 )
2011
49
The prevalence of congenital uterine anomalies in unselected and high-risk populations: a systematic review. ( 21705770 )
2011
50
Prevalence of uterine anomalies and their impact on early pregnancy in women conceiving after assisted reproduction treatment. ( 21337662 )
2011

Variations for Uterine Anomalies

Expression for Uterine Anomalies

Search GEO for disease gene expression data for Uterine Anomalies.

Pathways for Uterine Anomalies

Pathways related to Uterine Anomalies according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.68 CDKN2A MLH1 MSH2 MSH6 PTEN TP53
2
Show member pathways
12.55 CDKN2A ESR1 MSH6 PTEN TP53
3 12.53 CDKN2A ESR1 MLH1 MSH2 MSH6 PTEN
4
Show member pathways
12.47 CDKN2A ESR1 MLH1 PGR PTEN TP53
5
Show member pathways
12.34 CSH1 CSH2 ESR1 PTEN
6 12.3 CDKN2A MLH1 MSH2 MSH6 TP53
7 12.05 MLH1 MSH2 MSH6 TP53
8 11.9 MLH1 MSH2 PTEN TP53
9
Show member pathways
11.74 MLH1 MSH2 MSH6
10
Show member pathways
11.66 MSH2 MSH6 TP53
11 11.45 MLH1 MSH2 MSH6 TP53
12
Show member pathways
11.29 MLH1 MSH2 TP53
13 11.29 CYP19A1 ESR1 MSH2 MSH6 PTEN TP53
14 11.24 ESR1 PTEN TP53
15 11.22 CDKN2A MLH1 MSH2 MSH6 TP53
16 11.12 MSH2 MSH6 PTEN TP53
17 11.09 CYP19A1 MLH1 PGR
18 11.01 MLH1 MSH2 MSH6
19 10.13 CYP19A1 ESR1

GO Terms for Uterine Anomalies

Cellular components related to Uterine Anomalies according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.9 CDKN2A ESR1 HNF1B INSM1 MLH1 MSH2
2 MutSalpha complex GO:0032301 8.96 MSH2 MSH6
3 mismatch repair complex GO:0032300 8.8 MLH1 MSH2 MSH6

Biological processes related to Uterine Anomalies according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.78 CSH1 CSH2 TP53
2 response to glucose GO:0009749 9.74 HNF1B PTEN PTPRN
3 social behavior GO:0035176 9.7 MAPK8IP2 OXT PTEN
4 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.67 MLH1 MSH2 MSH6
5 maternal behavior GO:0042711 9.62 OXT PTEN
6 protein localization to chromatin GO:0071168 9.62 ESR1 MSH2
7 replicative senescence GO:0090399 9.61 CDKN2A TP53
8 growth hormone receptor signaling pathway GO:0060396 9.6 CSH1 CSH2
9 positive regulation of growth GO:0045927 9.59 CSH1 CSH2